NDAINTRAVENOUSSOLUTION
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
PEMETREXED DISODIUM (pemetrexed disodium) by Novartis is folate-dependent metabolic processes essential for cell replication. Approved for non-small cell lung cancer, malignant mesothelioma. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pemetrexed disodium is a folate-dependent metabolic inhibitor approved for non-small cell lung cancer and malignant mesothelioma, administered intravenously. It works by inhibiting thymidylate synthase, dihydrofolate reductase, and GARFT—key enzymes in nucleotide biosynthesis—thereby disrupting cell replication in rapidly dividing cancer cells. Once internalized and converted to polyglutamate forms, pemetrexed is retained in cells for sustained anti-cancer activity.
Peak
At peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable market position and sustained commercial activity but potential for team consolidation as alternatives emerge.
Mechanism of Action
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis…
Indications (2)
Worked on PEMETREXED DISODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.